CAS 1072833-77-2

Ixazomib

Description:

Ixazomib is a small molecule proteasome inhibitor primarily used in the treatment of multiple myeloma. It functions by disrupting the proteasome's ability to degrade ubiquitinated proteins, leading to the accumulation of pro-apoptotic factors and ultimately inducing cancer cell death. Ixazomib is characterized by its oral bioavailability, making it a convenient option for patients compared to traditional intravenous therapies. The compound exhibits a specific mechanism of action that targets the 26S proteasome, which is crucial for regulating various cellular processes, including the cell cycle and apoptosis. Ixazomib is often used in combination with other therapies, such as lenalidomide and dexamethasone, to enhance its efficacy. Its pharmacokinetics involve metabolism primarily through the liver, with a half-life that supports once-weekly dosing. As with many cancer therapies, potential side effects may include thrombocytopenia, gastrointestinal disturbances, and peripheral neuropathy, necessitating careful monitoring during treatment. Overall, Ixazomib represents a significant advancement in the therapeutic landscape for multiple myeloma, providing an effective oral treatment option for patients.

Formula: C₁₄H₁₉BCl₂N₂O₄

InChI: InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1

InChI key: InChIKey=MXAYKZJJDUDWDS-LBPRGKRZSA-N

SMILES: C(NCC(N[C@@H](CC(C)C)B(O)O)=O)(=O)C1=C(Cl)C=CC(Cl)=C1

Synonyms:

• MLN 2238
• B-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]boronic acid
• Ninlaro
• Boronic acid, B-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-
• Ixazomib

[(1R)-1-{2-[(2,5-dichlorophenyl)formamido]acetamido}-3-methylbutyl]boronic acid

CAS: 1072833-77-2

Formula: C₁₄H₁₉BCl₂N₂O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 361.0287

Ref: IN-DA0037YJ

Ixazomib

CAS: 1072833-77-2

Ixazomib

Purity: 98%

Molecular weight: 361.03g/mol

Ref: 54-OR1025727

Ixazomib

CAS: 1072833-77-2

Ixazomib

Purity: ≥98%

Molecular weight: 361.03g/mol

Ref: 54-BUP06961

Ixazomib

CAS: 1072833-77-2

Formula: C₁₄H₁₉BCl₂N₂O₄

Color and Shape: White To Off-White Solid

Molecular weight: 361.03

Ref: 4Z-I-088001

Ixazomib [MLN2238]

CAS: 1072833-77-2

Ref: 7W-GW1595

Ixazomib

CAS: 1072833-77-2

Ixazomib (MLN2238) is a boron-based peptide proteasome inhibitor targeting β5 site (IC50: 3.4 nM), also affecting β1 and β2 sites.

Formula: C₁₄H₁₉BCl₂N₂O₄

Purity: 98% - 98.92%

Color and Shape: Solid

Molecular weight: 361.03

Ref: TM-T2122

Ixazomib-d7

CAS: 1072833-77-2

Formula: C₁₄H₁₂D₇BCl₂N₂O₄

Molecular weight: 368.07

Ref: 4Z-I-088002

Ixazomib-13C2,15N

Controlled Product

CAS: 1072833-77-2

Applications Ixazomib-13C2,15N is derived from (αR)-(1S,2S,3R,5S)-Pinanediol-1-amino-3-methylbutane-1-boronate Trifluoroacetic Acid Salt (P458505), which is a Bortezomib (B675700) intermediate. A boronic acid dipeptide derivative as proteasome inhibitors.
References Kisselev, A., et al.: Chem. Biol., 8, 739 (2001), Kisselev, A., et al.: J. Biol. Chem., 278, 35869 (2003), Verdoes, M., et al.: Chem. Biol., 13, 1217 (2006)

Formula: C₁₂₁₃C₂H₁₉BCl₂N₁₅NO₄

Color and Shape: White To Off-White

Molecular weight: 364.01

Ref: TR-I942002

Ixazomib

CAS: 1072833-77-2

Proteosome inhibitor; antineoplastic

Formula: C₁₄H₁₉BCl₂N₂O₄

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 361.03 g/mol

Ref: 3D-FI65049

Ixazomib

Controlled Product

CAS: 1072833-77-2

Applications Ixazomib is a proteasome inhibitor that acts by preventing cell growth in solid tumours. It is an anticancer agent that is used to treat patients with multiple myeloma and is potentially neurotoxic.
References Anderson, K.: J. Nat. Comp. Canc. Net., 12, 808 (2014); Chattopadhyay, N., et al.: Mol. Cancer Ther., 12, B156 (2013); Vallet, S. & Podar, K.: Exp. Opin. Biol. Ther., 13, S35 (2013)

Formula: C₁₄H₁₉BCl₂N₂O₄

Color and Shape: Neat

Molecular weight: 361.03

Ref: TR-I942000